A study that examined 132 samples of IPMNs using a novel ligation test discovered that 66 % of the samples had GNAS mutations, 81 % had KRAS mutations, and 51 % had both GNAS and KRAS mutations.[46] According to another study, 172 IPMNs had 48 % GNAS mutations, 56 % KRAS mutations, and 31 % had both GNAS and KRAS mutations.[47] GNAS mutations were found in invasive tumours, high‐grade tumours, and low‐grade tumours. This evidence concerns the gene KRAS and neoplasm.